Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave s Q1 Revenue Rises 11 Percent as R&D Slides; Loss Unchanged

This article has been updated from a previous version, which incorrectly stated that revenues from licenses and royalties increased 19 percent, rather than revenues from grants.


NEW YORK, April 25 (GenomeWeb News) - Third Wave today said first-quarter revenues increased 11.3 percent as R&D spending dipped slightly and net losses remained roughly flat.


Total receipts for the three months ended March 31 increased to $7.9 million from $7.1 million year over year. Revenue from clinical product sales grew 52 percent to $4.7 million, though revenue from research products fell 21 percent to $3 million.


License and royalty receipts fell 71 percent to $27,000, while revenue from grants increased 19 percent to $142,000.


Third Wave said R&D spending in the quarter declined 8 percent to $2.3 million from the year-ago period.


Net loss remained flat at $4.4 million, or $.11 per share, the company said.


Third Wave said it had around $35.6 million in cash, equivalents, and short-term investments as of March 31.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.